Welcome to Carapinha & Consultants.

We are a Specialist Market Access Firm improving patient access through stronger pharmaceutical markets.

Achieving Pharmacoeconomic Excellence in South Africa

18 Jun

We shared a post on LinkedIn on the results of a systematic review that found half of the pharmacoeconomic studies in South Africa are good quality. The purpose of the post is to extend the discussion presented by the authors and to consider the future implications for pharmacoeconomic research in South Africa and the implementation of pharmacoeconomic […]

Webinar “creating value with accessed-based marketing”: themes and reflecting on a way-forward

26 May

Carapinha & Consultants partnered with eyeforpharma to bring a webinar on creating value with accessed-based marketing. The webinar was structured around 3 core questions that eyeforpharma’s Paul Simms used to facilitate the discussion. Question 1 The first question, “In order for the industry to move forward, pharma has to prioritize” generated interesting results. 69% of respondents […]

Webinar: “Remove barriers to entry by embracing an access-based approach to marketing”

19 May
eyeforpharmabanner

We’ve joined eyeforpharma as their Strategic Partner to bring you a free webinar: “Remove barriers to entry by embracing an access-based approach to marketing” on Tuesday 26th May 2:30-3:30 pm SAST. Pharma companies in South Africa have products with compelling economic value propositions, however reimbursement constraints have limited the up-take and patient access to new therapies. But how do we […]

China’s medicine pricing pro-market reforms

07 May
china

China’s National Development and Reform Commission announced earlier this week it would lift medicine price restrictions on most medicines except narcotics and psychotropics. The decision will shift price-setting decisions from regulators to the market and the Commission hopes it will improve competition and result in lower medicine prices. It is still early days whether this policy […]

Single Exit Price Legislation: A Source of Harm to Competition

07 May
policylaws

Background At the time of formulating the Single Exit Price legislation in South Africa; medicine price inflation, medicine price transparency, and medicine price uniformity were all significant problems in an unregulated medicines market. Medicines price inflation was in the double digits during the 1990s and early 2000’s; it was impossible to determine the true price […]